Groundbreaking treatment enhances the immune system's ability to fight cancer Holy Cross Health now offers bispecific therapy ...

Akeso and Summit Therapeutics’ giant-killing, PD-1xVEGF bispecific antibody ivonescimab has posted another phase 3 trial win ...

To permanently access this White Paper for free, fill out the short form below. Bispecific antibodies (bsAbs) represent a significant advancement in biologic therapeutics. However, their development ...

Analysts at BMO Capital Markets expect Summit and Akeso's HARMONi-6 readout to put some pressure on Merck and its blockbuster ...

Sanofi is continuing to splash the cash for autoimmune and immunology assets this spring by penning a new deal with ...

AstraZeneca and Daiichi Sankyo are gunning to get Enhertu a new first-line approval in HER2-positive breast cancer after a ...

Rapid Turnaround: Delivery of fully QC-analyzed antibodies within weeks of final ... clearly defined path to commercial terms. "Advancing bispecific programs requires both speed and access to ...

Geoffrey Shouse, DO, PhD, discusses what motivated this retrospective review of bispecific antibodies in diffuse large B-cell lymphoma at City of Hope.

Aclaris Therapeutics Inc. has gained IND clearance from the FDA for ATI-052, a bispecific anti-thymic stromal lymphopoietin (TSLP)/interleukin-4 receptor (IL-4R) monoclonal antibody being developed to ...

Rapid Turnaround: Delivery of fully QC-analyzed antibodies within weeks of final DNA vector validation ... Includes research-use rights with a clearly defined path to commercial terms. "Advancing ...